Skip to content Skip to footer
Subscribe Now
Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
VIEWPOINTS

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots

Shots:  Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis  The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
May 26, 2025

Read more

IPO Top 20 2024
TOP 20

Top 20 Healthcare IPOs of 2024

Shots: Initial Public Offerings (IPOs) serve as a strategic avenue for private healthcare companies to enhance liquidity, secure capital, and strengthen market presence. Beyond fundraising, going public often paves the way for strategic partnerships and expanded industry influence. Galderma led the IPO landscape in 2024, raising a staggering $2.54B, followed by BrightSpring Health Services and…
February 27, 2025

Read more

Viewpoints_Gerry Muhle
VIEWPOINTS

GAIN JPAC 2024: Gerry Muhle from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots:  GAIN JPAC is an emerging platform where leaders in aesthetics convene to share knowledge and advance patient treatment and safety  PharmaShots hosted Gerry Muhle, Head of Global Product Strategy at Galderma, who discussed the ‘Next by Galderma’ report, providing insights into the future of the aesthetics market and helping professionals better understand patient and…
December 30, 2024

Read more

Galderma
News

Galderma’s Nemluvio (Nemolizumab) Secures the US FDA’s Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD) 

Shots:    The US FDA has approved Nemluvio + TCS ± calcineurin inhibitors (TCI) to treat mod. to sev. atopic dermatitis in patients unresponsive to topical therapies  Approval was based on the P-III (ARCADIA) study of the combination vs PBO in patients (n=1,728; ≥12yrs.), showing significant skin clearance in both co-1EPs of IGA score (0/1) &…
December 13, 2024

Read more

Galderma
News

Galderma’s Nemluvio (Nemolizumab) Receives Positive CHMP Opinion to Treat Prurigo Nodularis (PN) and Atopic Dermatitis 

   Shots:    The CHMP's recommendation of Nemluvio (SC) for mod. to sev. atopic dermatitis (≥12yrs.) & prurigo nodularis in eligible ones for systemic therapy was based on P-III ARCADIA & OLYMPIA studies, respectively. Reviews are ongoing in Australia, Singapore, Switzerland, Canada, Brazil & South Korea, with more filings underway   ARCADIA 1 & 2 studies assessed…
December 13, 2024

Read more

Viewpoints_Baldo Scassellati Sforzolini
VIEWPOINTS

Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Galderma’s Nemluvio (nemolizumab) was recently approved by the US FDA for the treatment of adults with prurigo nodularis, following positive Phase III results from the OLYMPIA study.  Today at PharmaShots, we have Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma, to discuss the study’s design and the potential of Nemluvio in…
October 23, 2024

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]